OncoMatch/Clinical Trials/NCT07119463
Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
Is NCT07119463 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Human Serum Albumin Infusion for LAT Group and Human Serum Albumin Infusion for HAT Group for postoperative hypoalbuminemia.
Treatment: Human Serum Albumin Infusion for LAT Group · Human Serum Albumin Infusion for HAT Group — This study aims to evaluate the impact of goal-oriented albumin infusion on short-term postoperative outcomes in gastric cancer patients. It is a single-center, prospective, non-randomized controlled study. Patients are divided into two groups: the experimental group receives albumin infusion when serum albumin levels fall below 25 g/L, while the control group receives albumin infusion when levels fall below 30 g/L. The primary endpoint is the incidence of complications graded Clavien-Dindo III or above within 30 days post-surgery. Secondary endpoints include nutritional recovery, gastrointestinal function recovery, hospital stay duration, and overall complication rates. The study seeks to optimize perioperative albumin management strategies and improve clinical outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage I, II, III (TNM)
Excluded: Stage DISTANT METASTASIS
preoperative CT assessment of TNM stage I to III and undergoing laparoscopic gastric cancer surgery or open gastric cancer surgery
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
preoperative hemoglobin <70g/L excluded
Kidney function
renal insufficiency (serum creatinine >133umol/L) excluded
Liver function
severe liver insufficiency (Child Pugh class B or C) excluded
Cardiac function
severe cardiac insufficiency (NYHA class III and above) excluded
serious basic diseases: such as severe liver insufficiency (Child Pugh class B or C), renal insufficiency (serum creatinine>133umol/L), severe cardiac insufficiency (NYHA class III and above), severe pulmonary insufficiency (preoperative blood gas analysis PaO2 ≤ 60mmHg)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify